Dyslipidemia is characterized by a imbalance of certain lipids in the blood. Patients may either suffer from elevated levels of LDL cholesterol and/or triglycerides, or a reduced amount of HDL cholesterol. The imbalance causes an increased risk for developing atherosclerosis and subsequently heart attacks, strokes, angina, or peripheral arterial disease, which are a major cause of mortality worldwide.

Genetic predispositioning has been identified as the main cause for developing primary dyslipidemia, while lifestyle, acquired medical conditions and drug use are considered risk factors for developing secondary dyslipidemia. Although therapeutic lifestyle changes are widely considered to be the preferred method of managing dyslipidemia, administration of lipid-lowering drugs, commonly statins, is often indispensable. Unfortunately, not all patients respond to these therapies and detrimental side-effects such as myopathy and hepatotoxicity might occur, emphasizing the urgent need of safe and effective new treatments.

The new scientific advances coming through from the laboratory need clinical trials that are conducted efficiently and at the right research centers. However, recruiting a vast number of suitable dyslipidemia patients within a limited time frame at affordable costs, while maintaining high data quality and integrity can be a challenge. To overcome these hurdles, at Julius Clinical we have a dedicated expert team that is ready to provide you with the perfect tailor-made solution for your Dyslipidemia clinical trial.

Julius clinical provides three key success criteria for conducting clinical trials in Dyslipidemia:
1. Scientific excellence through our close working relationship with global Key Opinion Leaders in the Dyslipidemia field, Prof. Alings and Dr. Cabezas.
2. Operational in-house expertise and a track record in running large CVO and CV studies
3. A global and committed scientific network of academic leaders who guarantee access to expert sites and patient populations across the world